Legend Biotech (LEGN) Stock: Buy, Sell, or Hold?
LEGN - Legend Biotech Corporation American Depositary Shares
$18.57
-0.75 (-3.88%)
âŧ
5d:
-2.83%
30d:
-15.17%
90d:
-33.77%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When LEGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: LEGN is fairly priced but lacks strong directional signals. At -5.7% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: LEGN is fairly priced but lacks strong directional signals. At -5.7% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$23.93
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$14.86
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: LEGN is currently trading at $18.57, which is considered slightly low relative to its 30-day fair value range of $18.18 to $20.86. From a valuation perspective, the stock is trading at a discount (Forward PE: 27.2) compared to its historical average (32.4). Remarkably, the market is currently pricing in an annual earnings decline of 5.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, LEGN is in a strong downtrend. Immediate support is located at $17.81, while resistance sits at $20.00. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $46.50 (+150.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LEGN is in a strong downtrend. Immediate support is located at $17.81, while resistance sits at $20.00. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $46.50 (+150.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$18.18 -
$20.86
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (44/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.9%)
- BULLISH: Trading 150.4% below Wall St target ($46.50)
- WARNING: Composite score 46/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$18.18 -
$20.86
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$17.81
Resistance Level
$20.00
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
27.18
Wall Street Target
$46.50
(+150.4%)
Revenue Growth (YoY)
51.9%
Profit Margin
-7.2%
Valuation Discount vs History
-5.7% cheaper
PE vs Historical
27.2 vs 32.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.7%
(market-implied from PE analysis)
1-Year Target
$17.51
(-6%)
2-Year Target
$16.51
(-11%)
3-Year Target
$15.57
(-16%)
3-Yr Target (if PE normalizes)
(PE: 27â32)
$18.56
(0%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 27.2 to 32.4
Stabilization Target:
$22.13
(+19.2%)
PE Expansion Potential:
+19.2%
Share & Embed Analysis
Last updated: October 02, 2026 8:27 PM ET
Data refreshes hourly during market hours. Next update: 9:27 PM
Data refreshes hourly during market hours. Next update: 9:27 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LEGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 56 HOLD |
|
ACAD
ACADIA Pharmaceuticals IâĻ |
BUY
20 analysts |
$32 | 62 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 51 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
10 analysts |
$70 | 68 BUY |
